Revision history of "The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities" (Q37668618)

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

3 September 2024

7 March 2024

4 September 2022

1 May 2021

10 June 2020

26 July 2019

14 November 2018

30 August 2018

21 March 2018

22 August 2017

21 August 2017